Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02982993 · ClinicalTrials.gov registry record

Hepatitis C Infection in World Trade Center Responders

A clinical trial of Hepatitis C Infection, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
3,906
Enrollment target
1
Study location

NCT02982993 is a study of Hepatitis C Infection that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 3,906 participants, above the 81-participant average among 3 other Hepatitis C Infection trials with a reported enrollment target (4722% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02982993, a study of Hepatitis C Infection, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
3,906 participants
Enrollment target
1
Study location

Study Summary

This study provides Hepatitis C virus screening to the members of the World Trade Center Health Program followed at the Icahn School of Medicine at Mount Sinai born during 1945-1965, and linkage to care for those found infected. The study will also determine if exposure to human remains, blood and/or bodily fluids during the World Trade Center Health Program activities are associated with Hepatitis C virus infection. These findings would be relevant to the larger United States population, especially to persons born during 1945-1965 who are at high risk of Hepatitis C virus infection.

Conditions Studied

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 3,906 participants
Start Date 2016-12
Est. Completion 2018-07-12

What the Registry Record Tells You About NCT02982993

The ClinicalTrials.gov registry entry for NCT02982993 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,906 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 81-participant average among 3 other Hepatitis C Infection trials with a reported enrollment target (4722% higher). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatitis C Infection appearing as the primary indexed condition, and to 0 interventions.

NCT02982993 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT02982993 about?

NCT02982993 is a clinical study titled "Hepatitis C Infection in World Trade Center Responders". This study provides Hepatitis C virus screening to the members of the World Trade Center Health Program followed at the Icahn School of Medicine at Mount Sinai born during 1945-1965, and linkage to care for those found infected. The study will also determine if exposure to human remains, blood and/o...

What is the current status of trial NCT02982993?

This trial is currently completed. The enrollment target is 3,906 participants. The study started on 2016-12. Estimated completion is 2018-07-12.

What conditions does trial NCT02982993 study?

This clinical trial studies the following conditions: Hepatitis C Infection.

Who is sponsoring clinical trial NCT02982993?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02982993 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hepatitis C Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.